vector

TCR redirected T cells for cancer therapy 1:46
TCR redirected T cells for cancer therapy
Chiara Bonini • 1 Apr 2022
Impact of COVID-19 on the advanced therapies sector 1:34
Impact of COVID-19 on the advanced therapies sector
Christian Schneider • 29 Oct 2021
Remaining issues in developing advanced therapies 2:12
Remaining issues in developing advanced therapies
Christian Schneider • 29 Oct 2021
Addressing the regulatory barriers advanced therapies face 1:19
Addressing the regulatory barriers advanced therapies face
Christian Schneider • 29 Oct 2021
The landscape of cell therapy for solid tumors 1:22
The landscape of cell therapy for solid tumors
Sven Kili • 5 Oct 2021
Vector-based therapies for metabolic disorders 3:09
Vector-based therapies for metabolic disorders
Gloria Gonzalez-Aseguinolaza • 18 May 2021
Novel oncolytic Ad6 vectors for cancer therapy 2:05
Novel oncolytic Ad6 vectors for cancer therapy
Margarita Romanenko • 13 May 2021
The need for next-gen AAV vectors 1:14
The need for next-gen AAV vectors
Arun Srivastava • 17 May 2021
NextGen & GenX AAV vectors for DMD gene therapy 3:49
NextGen & GenX AAV vectors for DMD gene therapy
Arun Srivastava • 18 May 2021
Synthetic AAV vectors for gene therapy of hemophilia in children 4:15
Synthetic AAV vectors for gene therapy of hemophilia in children
Arun Srivastava • 18 May 2021
The future impact of COVID-19 on the gene therapy sector 2:12
The future impact of COVID-19 on the gene therapy sector
Nicole Faust • 9 Apr 2021
The content of VJRegenMed is intended for healthcare professionals